These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

722 related articles for article (PubMed ID: 29706008)

  • 41. Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials.
    Papp KA; Signorovitch J; Ramakrishnan K; Yu AP; Gupta SR; Bao Y; Mulani PM
    Clin Drug Investig; 2011; 31(1):51-60. PubMed ID: 20932070
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Depression Symptoms Predict Worse Clinical Response to Etanercept Treatment in Psoriasis Patients.
    Jin W; Zhang S; Duan Y
    Dermatology; 2019; 235(1):55-64. PubMed ID: 30408786
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Guselkumab for the treatment of adults with moderate to severe plaque psoriasis.
    Puig L
    Expert Rev Clin Immunol; 2019 Jun; 15(6):589-597. PubMed ID: 30920855
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Body Region Involvement and Quality of Life in Psoriasis: Analysis of a Randomized Controlled Trial of Adalimumab.
    Armstrong AW; Villanueva Quintero DG; Echeverría CM; Gu Y; Karunaratne M; Reyes Servín O
    Am J Clin Dermatol; 2016 Dec; 17(6):691-699. PubMed ID: 27815915
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Assessing the Short-Term Efficacy and Safety of Guselkumab for Moderate-to-Severe Plaque Psoriasis: Meta-Analysis of Randomized Controlled Trials.
    Yang J; Wang Z; Zhang X
    J Immunol Res; 2020; 2020():4975628. PubMed ID: 32724829
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study.
    Ferris LK; Ott E; Jiang J; Hong HC; Li S; Han C; Baran W
    J Dermatolog Treat; 2020 Mar; 31(2):152-159. PubMed ID: 30887876
    [No Abstract]   [Full Text] [Related]  

  • 47. Pruritus and quality of life in moderate-to-severe plaque psoriasis: post hoc explorative analysis from the PRISTINE study.
    Mrowietz U; Chouela EN; Mallbris L; Stefanidis D; Marino V; Pedersen R; Boggs RL
    J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1114-20. PubMed ID: 25376448
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serious Gastrointestinal-Related Adverse Events Among Psoriasis Patients Treated With Guselkumab in VOYAGE 1 and VOYAGE 2.
    Foley P; Reich K; Blauvelt A; Bagel J; Langley RG; Miller M; Ramachandran P; Yang YW; Shen YK; You Y; Lebwohl M; Griffiths CEM
    J Drugs Dermatol; 2021 Aug; 20(8):855-860. PubMed ID: 34397205
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1.
    Griffiths CEM; Papp KA; Song M; Miller M; You Y; Shen YK; Han C; Blauvelt A
    J Dermatolog Treat; 2022 Mar; 33(2):848-856. PubMed ID: 32660282
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of Adalimumab Compared With Methotrexate or Placebo Stratified by Baseline BMI in a Randomized Placebo-Controlled Trial in Patients With Psoriasis.
    Prussick R; Unnebrink K; Valdecantos WC
    J Drugs Dermatol; 2015 Aug; 14(8):864-8. PubMed ID: 26267731
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis.
    Orbai AM; Chakravarty SD; You Y; Shawi M; Yang YW; Merola JF
    Dermatol Ther (Heidelb); 2023 Nov; 13(11):2859-2868. PubMed ID: 37713133
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.
    Blauvelt A; Leonardi C; Elewski B; Crowley JJ; Guenther LC; Gooderham M; Langley RG; Vender R; Pinter A; Griffiths CEM; Tada Y; Elmaraghy H; Lima RG; Gallo G; Renda L; Burge R; Park SY; Zhu B; Papp K;
    Br J Dermatol; 2021 Jun; 184(6):1047-1058. PubMed ID: 32880909
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study.
    Talamonti M; Malara G; Natalini Y; Bardazzi F; Conti A; Chiricozzi A; Mugheddu C; Gisondi P; Piaserico S; Pagnanelli G; Amerio P; Potenza C; Cantoresi F; Fargnoli MC; Balato A; Loconsole F; Offidani A; Bonifati C; Prignano F; Bartezaghi M; Rausa A; Aloisi E; Orsenigo R; Costanzo A;
    Acta Derm Venereol; 2021 Mar; 101(3):adv00422. PubMed ID: 33269404
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial.
    Leonardi C; Langley RG; Papp K; Tyring SK; Wasel N; Vender R; Unnebrink K; Gupta SR; Valdecantos WC; Bagel J
    Arch Dermatol; 2011 Apr; 147(4):429-36. PubMed ID: 21173304
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials.
    Papp KA; Armstrong AW; Reich K; Karunaratne M; Valdecantos W
    Am J Clin Dermatol; 2016 Feb; 17(1):79-86. PubMed ID: 26547918
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treating Moderate-to-Severe Plaque Psoriasis With Guselkumab: A Review of Phase II and Phase III Trials.
    Howell ST; Cardwell LA; Feldman SR
    Ann Pharmacother; 2018 Apr; 52(4):380-387. PubMed ID: 29134822
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.
    Abrouk M; Nakamura M; Zhu TH; Farahnik B; Koo J; Bhutani T
    J Dermatolog Treat; 2017 Sep; 28(6):488-491. PubMed ID: 28042711
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials.
    Papp KA; Yang M; Sundaram M; Jarvis J; Betts KA; Bao Y; Signorovitch JE
    Value Health; 2018 Jan; 21(1):1-8. PubMed ID: 29304933
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study.
    Sano S; Kubo H; Morishima H; Goto R; Zheng R; Nakagawa H
    J Dermatol; 2018 May; 45(5):529-539. PubMed ID: 29569397
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Etanercept reduces anxiety and depression in psoriasis patients, and sustained depression correlates with reduced therapeutic response to etanercept.
    Yang A; Xin X; Yang W; Li M; Yang W; Li L; Liu X
    Ann Dermatol Venereol; 2019 May; 146(5):363-371. PubMed ID: 31047699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.